Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $578.2 million.

  • Ligand Pharmaceuticals' Retained Earnings rose 908.24% to $578.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $578.2 million, marking a year-over-year increase of 908.24%. This contributed to the annual value of $499.0 million for FY2024, which is 80.16% down from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' Retained Earnings is $578.2 million, which was up 908.24% from $461.4 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' Retained Earnings' 5-year high stood at $589.2 million during Q1 2024, with a 5-year trough of $410.1 million in Q1 2021.
  • In the last 5 years, Ligand Pharmaceuticals' Retained Earnings had a median value of $468.8 million in 2022 and averaged $486.2 million.
  • Per our database at Business Quant, Ligand Pharmaceuticals' Retained Earnings surged by 1954.99% in 2024 and then tumbled by 2251.05% in 2025.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Retained Earnings stood at $449.1 million in 2021, then grew by 0.39% to $450.9 million in 2022, then increased by 11.57% to $503.0 million in 2023, then dropped by 0.8% to $499.0 million in 2024, then grew by 15.88% to $578.2 million in 2025.
  • Its Retained Earnings stands at $578.2 million for Q3 2025, versus $461.4 million for Q2 2025 and $456.5 million for Q1 2025.